EP 3558379 A1 20191030 - PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY
Title (en)
PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY
Title (de)
PHARMAZEUTISCHE DARREICHUNGSFORMEN ENTHALTEND INHIBITOREN VON TASK-1 UND TASK-3 KANÄLEN UND DEREN VERWENDUNG FÜR DIE THERAPIE VON ATEMSTÖRUNGEN
Title (fr)
FORMES PHARMACEUTIQUES CONTENANT DES INHIBITEURS DES CANAUX TASK-1 ET TASK-3 ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES RESPIRATOIRES
Publication
Application
Priority
- EP 16205686 A 20161221
- EP 17157800 A 20170224
- EP 2017082545 W 20171213
Abstract (en)
[origin: WO2018114503A1] The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.
IPC 8 full level
A61K 47/10 (2017.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/496 (2006.01)
CPC (source: EP KR US)
A61K 9/0043 (2013.01 - EP KR US); A61K 9/08 (2013.01 - EP KR); A61K 31/496 (2013.01 - EP KR US); A61K 47/02 (2013.01 - KR); A61K 47/10 (2013.01 - EP KR US); A61K 47/12 (2013.01 - KR); A61K 47/26 (2013.01 - KR US); A61P 9/00 (2017.12 - EP); A61P 9/06 (2017.12 - EP); A61P 11/00 (2017.12 - EP KR); A61P 11/16 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 25/20 (2017.12 - EP)
Citation (search report)
See references of WO 2018114503A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018114503 A1 20180628; AU 2017379247 A1 20190613; AU 2017379247 A8 20190718; BR 112019012569 A2 20191126; CA 3047428 A1 20180628; CL 2019001727 A1 20191129; CN 110114091 A 20190809; CO 2019006654 A2 20190628; CR 20190300 A 20190923; CU 20190060 A7 20200204; DO P2019000171 A 20190715; EC SP19044508 A 20190630; EP 3558379 A1 20191030; IL 267344 A 20190829; JO P20190141 A1 20190612; JP 2020502206 A 20200123; KR 20190099211 A 20190826; MA 47069 A 20210421; MX 2019007378 A 20190918; PE 20191241 A1 20190916; PH 12019501408 A1 20200210; TW 201834654 A 20181001; US 2020085734 A1 20200319; UY 37542 A 20180731
DOCDB simple family (application)
EP 2017082545 W 20171213; AU 2017379247 A 20171213; BR 112019012569 A 20171213; CA 3047428 A 20171213; CL 2019001727 A 20190620; CN 201780079708 A 20171213; CO 2019006654 A 20190621; CR 20190300 A 20171213; CU 20190060 A 20171213; DO 2019000171 A 20190619; EC DI201944508 A 20190621; EP 17821532 A 20171213; IL 26734419 A 20190613; JO P20190141 A 20170616; JP 2019533394 A 20171213; KR 20197017397 A 20171213; MA 47069 A 20171213; MX 2019007378 A 20171213; PE 2019001284 A 20171213; PH 12019501408 A 20190619; TW 106144530 A 20171219; US 201716471263 A 20171213; UY 37542 A 20171221